IRadimed (Germany) Insiders
| 46K Stock | 83.50 3.00 3.47% |
IRadimed employs about 148 people. The company is managed by 7 executives with a total tenure of roughly 346 years, averaging almost 49.0 years of service per executive, having 21.14 employees per reported executive. Breaking down IRadimed's management performance can provide insight into the firm performance.
| Roger Susi Chairman Chairman, Founder |
IRadimed |
IRadimed Management Team Effectiveness
The company has return on total asset (ROA) of 0.1578 % which means that it generated a profit of $0.1578 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2478 %, meaning that it generated $0.2478 on every $100 dollars invested by stockholders. IRadimed's management efficiency ratios could be used to measure how well IRadimed manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IRadimed's Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 1.6 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 7.8 M in 2026.Common Stock Shares Outstanding is likely to drop to about 13.2 M in 2026. Net Income Applicable To Common Shares is likely to drop to about 7.4 M in 2026The market capitalization of IRadimed is USD1.07 Billion. Over half of IRadimed's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Accordingly, these institutions are subject to different rules and regulations than regular investors in IRadimed. Please watch out for any change in the institutional holdings of IRadimed as this could mean something significant has changed or is about to change at the company. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 12.7 M | Current Value 12.7 M | Avarage Shares Outstanding 12.3 M | Quarterly Volatility 458.7 K |
IRadimed Workforce Comparison
IRadimed is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 2,099. IRadimed holds roughly 148 in number of employees claiming about 7% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.27 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.31 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.31. IRadimed Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. IRadimed Price Series Summation is a cross summation of IRadimed price series and its benchmark/peer.
IRadimed Notable Stakeholders
An IRadimed stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as IRadimed often face trade-offs trying to please all of them. IRadimed's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting IRadimed's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Roger Susi | Chairman, Founder | Profile | |
| Randy Waddell | Vice Marketing | Profile | |
| Jeff Chiprin | Chief Officer | Profile | |
| Lynn Neuhardt | Vice Development | Profile | |
| Chris Williamson | Executive Technology | Profile | |
| Matt Garner | Controller | Profile | |
| John Glenn | Chief Officer | Profile |
About IRadimed Management Performance
The success or failure of an entity such as IRadimed often depends on how effective the management is. IRadimed management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of IRadimed management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the IRadimed management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
IRadimed is entity of Germany. It is traded as Stock on STU exchange.
Please note, the imprecision that can be found in IRadimed's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IRadimed. Check IRadimed's Beneish M Score to see the likelihood of IRadimed's management manipulating its earnings.
IRadimed Workforce Analysis
Traditionally, organizations such as IRadimed use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare IRadimed within its industry.IRadimed Manpower Efficiency
Return on IRadimed Manpower
| Revenue Per Employee | 494.9K | |
| Revenue Per Executive | 10.5M | |
| Net Income Per Employee | 130K | |
| Net Income Per Executive | 2.7M | |
| Working Capital Per Employee | 450.9K | |
| Working Capital Per Executive | 9.5M |
Additional Tools for IRadimed Stock Analysis
When running IRadimed's price analysis, check to measure IRadimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRadimed is operating at the current time. Most of IRadimed's value examination focuses on studying past and present price action to predict the probability of IRadimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRadimed's price. Additionally, you may evaluate how the addition of IRadimed to your portfolios can decrease your overall portfolio volatility.